Overview
Clotting time is a basic screening test that measures the time taken for whole blood to form a visible clot under controlled laboratory conditions. It primarily evaluates the efficiency of the intrinsic and common coagulation pathways and reflects the activity of plasma clotting factors. The test is simple to perform and has been traditionally used to assess bleeding disorders and monitor anticoagulant therapy. Although newer automated coagulation tests are more precise, clotting time remains useful for basic assessment and educational purposes.
Symptoms
Clotting time testing is indicated in patients with symptoms suggestive of coagulation abnormalities. These include prolonged bleeding after minor injuries, easy bruising, recurrent epistaxis, gum bleeding, hemarthrosis, menorrhagia, or excessive bleeding during surgery. Patients on anticoagulant therapy or with liver disease may also show abnormal bleeding tendencies, prompting evaluation.
Causes
Prolonged clotting time occurs due to deficiency or dysfunction of coagulation factors involved in the intrinsic or common pathways. Common causes include hemophilia A and B, severe liver disease, vitamin K deficiency, disseminated intravascular coagulation, and dilutional coagulopathy following massive transfusion. Anticoagulant drugs such as heparin and warfarin also prolong clotting time. Reduced clotting time is uncommon and usually has no significant pathological implication, often reflecting technical or procedural variation.
Risk Factors
Risk factors for abnormal clotting time include inherited coagulation factor deficiencies, chronic liver disease, malabsorption syndromes, prolonged antibiotic use, and anticoagulant therapy. Patients undergoing major surgery, those with sepsis, trauma, or malignancy, and individuals with a family history of bleeding disorders are at higher risk. Improper sample collection, incorrect temperature, or delayed testing can affect results.
Prevention
While coagulation disorders cannot always be prevented, early detection through clotting time assessment helps reduce bleeding-related complications. Proper management of liver disease, correction of vitamin deficiencies, and careful monitoring of anticoagulant therapy lower the risk. Adherence to correct testing technique, prompt analysis, and correlation with other coagulation tests improves reliability. Early diagnosis and appropriate clinical intervention help prevent severe bleeding and improve patient outcomes.
